Differentiate between the proteasome inhibitors (PIs), outlining the efficacy and safety profiles, advantages and disadvantages, and quality of life impact of each
|
|
|
|
|
|
Select tailored treatment combinations for a cytogenetically high-risk multiple myeloma (MM) patient at first and second relapse
|
|
|
|
|
|
Expound the rationale for PI-based treatment combinations for patients with relapsed/refractory MM
|
|
|
|
|
|